Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study.
adverse events
antiretroviral therapy
bictegravir
drug reaction
rash
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
24
01
2020
accepted:
21
07
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
epublish
Résumé
Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predominantly African American overweight population, we found optimal virologic control and low discontinuation rates, with 4% discontinuing BIC/FTC/TAF due to rash, low platelets, loss of appetite, and insomnia.
Identifiants
pubmed: 32908943
doi: 10.1093/ofid/ofaa285
pii: ofaa285
pmc: PMC7470466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa285Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
AIDS. 2004 Dec 3;18(18):2391-400
pubmed: 15622315
Lancet HIV. 2019 Jun;6(6):e355-e363
pubmed: 31068270
Lancet HIV. 2018 Jul;5(7):e347-e356
pubmed: 29925490
Lancet. 2017 Nov 4;390(10107):2073-2082
pubmed: 28867499
Hum Immunol. 2001 Sep;62(9):1009-30
pubmed: 11543903